Press Release: Oncomedics Awarded France 2030 Plan Grant
Limoges, March 14, 2025 – Oncomedics, a biotechnology company specializing in the personalization of cancer treatments and a member of the Oncomedics Group, has been named a laureate of the France 2030 Plan under the "Industrialization and Health Capacities 2030" call for projects. This second distinction, following its recognition under the France Relance program in 2021, will enable the large-scale industrialization of its innovative medical device: the Oncogramme®.
Founded in 2006 in Limoges by Christophe Lautrette and Stéphanie Giraud, Oncomedics develops in vitro diagnostic medical devices to assist surgeons, pathologists, and oncologists in selecting the most effective cancer treatments for their patients. By fully integrating Oncomedics in 2022, Oncomedics continues its ambition to become a major European player in the life sciences sector.
A Strategic Project for the Future of Oncology Diagnostics
The awarded project focuses on the industrialization of reagent and media production required for the Oncogramme®, a device designed for the personalized treatment of metastatic colorectal cancer. This industrialization is crucial to support the commercial expansion of Oncomedics and to ensure secure production within France. Furthermore, this initiative will foster the development of innovative reagents, strengthening Oncomedics’ production capabilities in France.
Launched in October 2021 by the President of the Republic, the France 2030 Plan aims to transform key sectors of the French economy, including healthcare, through major technological and industrial innovations. In the Nouvelle-Aquitaine region alone, 615 projects have already received support, representing €1.163 billion in funding.
The Oncogramme® for Metastatic Colorectal Cancer
The Oncogramme® is an innovative medical device that predicts the efficacy of various cancer treatments on tumor cells directly derived from patients with metastatic colorectal cancer. In France, Oncomedics already markets the Oncogramme® within clinical studies, thanks to a temporary reimbursement under the "Forfait Innovation" program. This enables practitioners to select the most suitable treatments for each patient. Today, the company aims to accelerate its international expansion to bring this cutting-edge technology to patients and healthcare professionals worldwide.
Christophe Lautrette, Co-founder of Oncomedics, stated:
"Being awarded the France 2030 Plan grant marks a major milestone for Oncomedics and the Oncogramme®. It validates the scientific and industrial relevance of our approach, significantly strengthening our ability to offer innovative and effective diagnostic solutions to cancer patients."
Tushendan Rasiah, President of the Oncomedics Group, added:
"This government support validates our strategy of innovation and investment in France. The integration of Oncomedics into the Oncomedics Group aligns perfectly with our long-term vision: to become a European leader in diagnostics and biotechnology, particularly through products developed from our own research and development efforts."
Press Contacts
Gaël Gesbert – Director of Business Development-- info@oncomedics.com